Table 3 Initial antibiotic therapy by randomization group
| Â | Control group | PCT/Pyuria group |
|---|---|---|
All patients (intention-to-treat) | (n = 64) | (n = 61) |
First-line antibiotic therapy | Â | Â |
 Ciprofloxacin | 25 (39%) | 20 (33%) |
 Ceftriaxon | 18 (28%) | 18 (30%) |
 TMP-SMZ | 9 (14%) | 15 (25%) |
 Fosfomycin | 6 (9%) | 3 (5%) |
 Amoxicillin-Clavulanate | 5 (8%) | 1 (2%) |
 Other | 1 (2%) | 3 (5%) |
 NSAIDS | 0 | 1 (2%) |
Second-line antibiotic therapy | Â | Â |
 Ciprofloxacin | 10 (16%) | 15 (25%) |
 Ceftriaxon | 4 (6%) | 4 (7%) |
 TMP-SMZ | 4 (6%) | 3 (5%) |
 Amoxicillin-Clavulanate | 4 (6%) | 3 (5%) |
 Other | 3 (5%) | 5 (8%) |
Per-protocol population | (n = 52) | (n = 44) |
First-line antibiotic therapy | Â | Â |
 Ciprofloxacin | 20 (38%), efficacious in 90% | 15 (34%), efficacious in 87% |
 Ceftriaxon | 17 (33%), efficacious in 76% | 14 (32%), efficacious in 64% |
 TMP-SMZ | 6 (12%), efficacious in 67% | 9 (20%), efficacious in 44% |
 Fosfomycin | 5 (10%), efficacious in 100% | 2 (5%), efficacious in 100% |
 Amoxicillin-Clavulanate | 3 (6%), efficacious in 67% | 1 (2%), efficacious in 100% |
 Other | 1 (2%) | 2 (4%) |
 NSAIDS | 0 | 1 (2%) |
Second-line antibiotic therapy | Â | Â |
 Ciprofloxacin | 10 (19%), efficacious in 100% | 11 (25%), efficacious in 82% |
 Ceftriaxon | 3 (6%), efficacious in 67% | 4 (9%), efficacious in 100% |
 TMP-SMZ | 3 (6%), efficacious in 100% | 3 (7%), efficacious in 100% |
 Amoxicillin-Clavulanate | 4 (8%), efficacious in 100% | 2 (5%), efficacious in 100% |
 Other | 5 (10%) | 3 (7%) |